Literature DB >> 19232015

Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues.

Satu Luhtala1, Anu Vaajanen, Olli Oksala, Jarkko Valjakka, Heikki Vapaatalo.   

Abstract

PURPOSE: An active local renin-angiotensin system (RAS) has recently been found in the human eye. The aim of the present study was to compare the activities of central RAS enzymes (ACE1 and 2) in porcine ocular tissues, morphologically and physiologically close to the human eye. In addition, the effects of three ACE-inhibitory tripeptides on these enzymes were evaluated.
METHODS: Enucleated fresh porcine eyes were used. Activities of ACE1 and ACE2 and their inhibition by bioactive tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) as well as by a standard ACE-inhibitor captopril were assayed in the vitreous body, the retina and the ciliary body using fluorometric detection methods.
RESULTS: Activity of ACE1 as well as ACE2 was found in all tissues evaluated. ACE1 activity was markedly higher in the ciliary body (3.7 +/- 0.7 mU/mg protein) than in retina (0.2 +/- 0.02 mU/mg), whereas ACE2 activities in the ciliary body (0.2 +/- 0.02 mU/mg) and retina (0.2 +/- 0.01 mU/mg) were at the same level. In the vitreous body ACE1 activity (8.2 +/- 0.31 nmol/min/mL) was manifold compared to that of ACE2 (0.1 +/- 0.02 nmol/min/mL). The tripeptides inhibited ACE1 at one-thousandth of the concentration needed to inhibit ACE2. All peptides studied evinced about equal inhibitory activities.
CONCLUSION: To our knowledge the present findings constitute the first evidence of ACE2 activity in the ciliary and vitreous bodies, in addition to previously described activity in the retina. The known favorable effects of ACE2 products vs. those of ACE1 suggest a counterbalancing interaction of these two enzyme homologues in physiological regulation of ocular circulation and pressure and possible protective role in certain ophthalmic disorders such as glaucoma and diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232015     DOI: 10.1089/jop.2008.0081

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  24 in total

1.  Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.

Authors:  Yiguo Qiu; Pollob Kumar Shil; Ping Zhu; Hongxia Yang; Amrisha Verma; Bo Lei; Qiuhong Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

2.  1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.

Authors:  Galina D Kutuzova; B'ann T Gabelt; Julie A Kiland; Elizabeth A Hennes-Beann; Paul L Kaufman; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

3.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

4.  Milk Products Containing Bioactive Tripeptides Have an Antihypertensive Effect in Double Transgenic Rats (dTGR) Harbouring Human Renin and Human Angiotensinogen Genes.

Authors:  Tiina Jauhiainen; Taru Pilvi; Zhong Jian Cheng; Hannu Kautiainen; Dominik N Müller; Heikki Vapaatalo; Riitta Korpela; Eero Mervaala
Journal:  J Nutr Metab       Date:  2009-11-30

5.  Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2.

Authors:  Giselle Foureaux; José C Nogueira; Bárbara S Nogueira; Gustavo O Fulgêncio; Gustavo B Menezes; Simone O A Fernandes; Valbert N Cardoso; Renata S Fernandes; Gabriel P Oliveira; Juçara R Franca; André A G Faraco; Mohan K Raizada; Anderson J Ferreira
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-21       Impact factor: 4.799

Review 6.  Ocular Manifestations of Patients with Coronavirus Disease 2019: A Comprehensive Review.

Authors:  Amirhossein Roshanshad; Mohammad Ali Ashraf; Romina Roshanshad; Ali Kharmandar; Seyed Alireza Zomorodian; Hossein Ashraf
Journal:  J Ophthalmic Vis Res       Date:  2021-04-29

7.  Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.

Authors:  Giselle Foureaux; Juçara Ribeiro Franca; José Carlos Nogueira; Gustavo de Oliveira Fulgêncio; Tatiana Gomes Ribeiro; Rachel Oliveira Castilho; Maria Irene Yoshida; Leonardo Lima Fuscaldi; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Sebastião Cronemberger; André Augusto Gomes Faraco; Anderson José Ferreira
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

8.  Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina.

Authors:  G Foureaux; B S Nogueira; D C O Coutinho; M K Raizada; J C Nogueira; A J Ferreira
Journal:  Braz J Med Biol Res       Date:  2015-09-29       Impact factor: 2.590

9.  The expression of Mas-receptor of the renin-angiotensin system in the human eye.

Authors:  A Vaajanen; G Kalesnykas; H Vapaatalo; H Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-14       Impact factor: 3.117

10.  Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition?

Authors:  Aino Siltari; Riikka Viitanen; Sampo Kukkurainen; Heikki Vapaatalo; Jarkko Valjakka
Journal:  Biologics       Date:  2014-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.